RaySearch releases version 2.5 of RayStation treatment planning system

NewsGuard 100/100 Score

RaySearch Laboratories AB (STO:RAYB) announces that version 2.5 of RaySearch's RayStation® treatment planning system has been released for clinical use in Europe and USA and is pending regulatory approval in Canada. The new version includes a wide range of new features and improvements.

RayStation® 2.5 includes all of RaySearch's market-leading optimization algorithms for VMAT, IMRT and 3D-CRT alongside a comprehensive set of tools for traditional 3D-CRT planning. This means that the system can be used clinically for treatment planning of all various treatment modalities of photon therapy. RayStation® 2.5 also has full support for combining all of these techniques in the same treatment. In addition, the new version includes improvements of RaySearch's unique multi-criteria optimization (MCO) solution for IMRT. This highly intuitive tool lets the clinician evaluate the impact of changing different treatment priorities in real-time, which has a large potential to speed up the time-consuming treatment planning optimization process. The MCO solution has been developed in collaboration with Massachusetts General Hospital in Boston, USA.

From the start, RayStation® was designed to handle 4D adaptive radiation therapy and the new release includes groundbreaking features in this field. Using advanced deformable registration algorithms, RayStation® 2.5 allows the users to perform dose tracking. This offers the possibility to perform accurate dose accumulation of any delivered or planned dose to any patient geometry using any combination of CT, MR, PET and 4D-CT data sets. RayStation® is the first treatment planning system that lets the clinicians monitor the impact of a changing patient geometry as the treatment progresses, and seamlessly adjust the treatment in the same system. The dose tracking functionality has been developed in collaboration with Princess Margaret Hospital in Toronto, Canada and is available for installation in Europe but is pending regulatory clearance in USA and Canada.

In addition to the new features, RayStation® 2.5 includes major improvements and performance enhancements that further facilitate and speed up the treatment planning process. For example, the collapsed cone clinical dose engine has been reimplemented, now offering unmatched speed, and the DICOM communication capabilities have been further improved. Examples in the usability area include extensive use of templates throughout the system, unlimited undo functionality and all sorts of keyboard shortcuts that are expected in modern software.

"We are very proud that we now can offer the first complete version of RayStation®. The system is now ready to be the workhorse for all photon treatments for all types of clinics, from smaller ones to large university hospitals with very advanced needs", says Johan Löf, CEO of RaySearch.

"We have a long-standing reputation of excellence in the field of optimization and firmly believe that we have now taken the lead in the field of adaptive therapy as well. I am convinced that the combination of optimization and adaptation is the future of radiation therapy and we fully intend to stay in the forefront of this development. We will continue to work closely with our customers and research partners to build new features and refine the system at a very high pace", concludes Johan Löf.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study finds lack of preventative care for children with sickle cell anemia